These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 18316572)

  • 21. hVps37A Status affects prognosis and cetuximab sensitivity in ovarian cancer.
    Wittinger M; Vanhara P; El-Gazzar A; Savarese-Brenner B; Pils D; Anees M; Grunt TW; Sibilia M; Holcmann M; Horvat R; Schemper M; Zeillinger R; Schöfer C; Dolznig H; Horak P; Krainer M
    Clin Cancer Res; 2011 Dec; 17(24):7816-27. PubMed ID: 22016507
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epithelial-to-mesenchymal transition and c-myc expression are the determinants of cetuximab-induced enhancement of squamous cell carcinoma radioresponse.
    Skvortsova I; Skvortsov S; Raju U; Stasyk T; Riesterer O; Schottdorf EM; Popper BA; Schiestl B; Eichberger P; Debbage P; Neher A; Bonn GK; Huber LA; Milas L; Lukas P
    Radiother Oncol; 2010 Jul; 96(1):108-15. PubMed ID: 20451273
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma.
    Inoue K; Slaton JW; Perrotte P; Davis DW; Bruns CJ; Hicklin DJ; McConkey DJ; Sweeney P; Radinsky R; Dinney CP
    Clin Cancer Res; 2000 Dec; 6(12):4874-84. PubMed ID: 11156247
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidermal growth factor receptor-mediated autocrine and paracrine stimulation of human transitional cell carcinoma.
    Gleave ME; Hsieh JT; Wu HC; Hong SJ; Zhau HE; Guthrie PD; Chung LW
    Cancer Res; 1993 Nov; 53(21):5300-7. PubMed ID: 8221665
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies.
    Riemer AB; Kurz H; Klinger M; Scheiner O; Zielinski CC; Jensen-Jarolim E
    J Natl Cancer Inst; 2005 Nov; 97(22):1663-70. PubMed ID: 16288119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cetuximab insufficiently inhibits glioma cell growth due to persistent EGFR downstream signaling.
    Hasselbalch B; Lassen U; Poulsen HS; Stockhausen MT
    Cancer Invest; 2010 Oct; 28(8):775-87. PubMed ID: 20504227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MMP9, Cyclin D1 and β-Catenin Are Useful Markers of p16-positive Squamous Cell Carcinoma in Therapeutic EGFR Inhibition In Vitro.
    Umbreit C; Erben P; Faber A; Hofheinz RD; Aderhold C; Weiss C; Hoermann K; Wenzel A; Schultz JD
    Anticancer Res; 2015 Jul; 35(7):3801-10. PubMed ID: 26124325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of thymosin β4 in the regulation of epithelial-mesenchymal transformation in urothelial carcinoma.
    Wang ZY; Zeng FQ; Zhu ZH; Jiang GS; Lv L; Wan F; Dong R; Xiao XY; Xing SA
    Urol Oncol; 2012; 30(2):167-76. PubMed ID: 20864366
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidermal growth factor receptor status and the response of bladder carcinoma cells to erlotinib.
    Jacobs MA; Wotkowicz C; Baumgart ED; Neto BS; Rieger-Christ KM; Bernier T; Cohen MS; Libertino JA; Summerhayes IC
    J Urol; 2007 Oct; 178(4 Pt 1):1510-4. PubMed ID: 17707060
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cetuximab promotes immunotoxicity against rhabdomyosarcoma in vitro.
    Herrmann D; Seitz G; Warmann SW; Bonin M; Fuchs J; Armeanu-Ebinger S
    J Immunother; 2010 Apr; 33(3):279-86. PubMed ID: 20445348
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer.
    Bäumer S; Bäumer N; Appel N; Terheyden L; Fremerey J; Schelhaas S; Wardelmann E; Buchholz F; Berdel WE; Müller-Tidow C
    Clin Cancer Res; 2015 Mar; 21(6):1383-94. PubMed ID: 25589625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epidermal growth factor receptor function in the human urothelium.
    Wasén C; Ekstrand M; Levin M; Giglio D
    Int Urol Nephrol; 2018 Apr; 50(4):647-656. PubMed ID: 29508172
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antitumor effect and enhancement of cytotoxic drug activity by cetuximab in nasopharyngeal carcinoma cells.
    Sung FL; Poon TC; Hui EP; Ma BB; Liong E; To KF; Huang DP; Chan AT
    In Vivo; 2005; 19(1):237-45. PubMed ID: 15796181
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relevance of E-cadherin expression to EGFR-TKI molecular targeted therapy sensitivity/resistance and its clinical significance.
    Xing RC; Zheng J; Zheng WH; Qin ZP; Liu W; Yao RC
    Genet Mol Res; 2015 May; 14(2):5785-92. PubMed ID: 26125777
    [TBL] [Abstract][Full Text] [Related]  

  • 35. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy.
    Adam L; Zhong M; Choi W; Qi W; Nicoloso M; Arora A; Calin G; Wang H; Siefker-Radtke A; McConkey D; Bar-Eli M; Dinney C
    Clin Cancer Res; 2009 Aug; 15(16):5060-72. PubMed ID: 19671845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relevance of MET activation and genetic alterations of KRAS and E-cadherin for cetuximab sensitivity of gastric cancer cell lines.
    Heindl S; Eggenstein E; Keller S; Kneissl J; Keller G; Mutze K; Rauser S; Gasteiger G; Drexler I; Hapfelmeier A; Höfler H; Luber B
    J Cancer Res Clin Oncol; 2012 May; 138(5):843-58. PubMed ID: 22290393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Willet F. Whitmore, Jr., Lectureship: blockade of epidermal growth factor receptors as anticancer therapy.
    Mendelsohn J; Dinney CP
    J Urol; 2001 Apr; 165(4):1152-7. PubMed ID: 11257658
    [No Abstract]   [Full Text] [Related]  

  • 38. DNMT1: an emerging target in the treatment of invasive urinary bladder cancer.
    Dhawan D; Ramos-Vara JA; Hahn NM; Waddell J; Olbricht GR; Zheng R; Stewart JC; Knapp DW
    Urol Oncol; 2013 Nov; 31(8):1761-9. PubMed ID: 22609058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of cetuximab and panitumumab in oral squamous cell carcinoma cell lines: prognostic value of MAGE-A subgroups for treatment success.
    Hartmann S; Kriegebaum U; Küchler N; Lessner G; Brands RC; Linz C; Schneider T; Kübler AC; Müller-Richter UD
    J Craniomaxillofac Surg; 2013 Oct; 41(7):623-9. PubMed ID: 23375534
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer.
    McConkey DJ; Choi W; Marquis L; Martin F; Williams MB; Shah J; Svatek R; Das A; Adam L; Kamat A; Siefker-Radtke A; Dinney C
    Cancer Metastasis Rev; 2009 Dec; 28(3-4):335-44. PubMed ID: 20012924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.